Eton Pharmaceuticals To Report Third Quarter 2026 Financial Results On Thursday, November 5, 2026
| Participant Call Link: | Click Here |
| Webcast: | Click Here |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: ....
The live webcast can also be accessed on the Investors section of Eton's website at . An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has twelve rare disease products: KHINDIVI ®, INCRELEX®, ALKINDI SPRINKLE®, DESMODATM, GALZIN®, HEMANGEOL®, PKU GOLIKE®, IMPAVIDO®, LIBERVANT®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ASN-001, AMGLIDIA®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at .
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: ...
Source: Eton Pharmaceuticals, Inc.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment